<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202512</url>
  </required_header>
  <id_info>
    <org_study_id>1333.43</org_study_id>
    <secondary_id>2014-000320-20</secondary_id>
    <nct_id>NCT02202512</nct_id>
  </id_info>
  <brief_title>Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers</brief_title>
  <official_title>Effect of Repeated Oral Doses of BI 1060469, BI 1021958 and Active Controls, Cimetidine and Naproxen, on Measured GFR Via Renal Clearance of Iohexol in Healthy Male Subjects (a Phase I Study; Single-blind, Randomized, Placebo-controlled Within BI Groups and Open-label for the Active Controls)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Main objective is to investigate the measured glomerular filtration rate (mGFR) as assessed&#xD;
      by iohexol clearance in healthy male normovolemic subjects after oral administration of&#xD;
      single and repeated doses of BI 1060469, and BI 1021958.&#xD;
&#xD;
      The secondary objective of this trial is to investigate the glomerular filtration rate (GFR)&#xD;
      as assessed by 24 hours creatinine clearance in healthy male normovolemic subjects after oral&#xD;
      administration of single and repeated doses of BI 1060469, and BI 1021958.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measured glomerular filtration rate (mGFR) based on renal iohexol clearance</measure>
    <time_frame>up to day 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>measured urinary 24-hour creatinine clearance</measure>
    <time_frame>up to day 11</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1060469 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low-Dose,Tablet,oral administration with 240 ml water,over 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1060469 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose,Tablets,oral administration with 240 ml water, over 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cimetidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1021958</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-Dose,Tablets,oral administration with 240 ml water, over 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cimetidine</intervention_name>
    <arm_group_label>Cimetidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1021958</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1060469 high dose</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1060469 low dose</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1060469 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1021958</intervention_name>
    <description>tablets</description>
    <arm_group_label>BI 1021958</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the investigators assessment, as based on the&#xD;
             following criteria: a complete medical history including a physical examination, vital&#xD;
             signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and&#xD;
             clinical laboratory tests, including negative test result on occult blood in stool&#xD;
             (only for subjects assigned to Naproxen)&#xD;
&#xD;
          -  Age 18 to 45 years (incl.)&#xD;
&#xD;
          -  Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with good clinical practice (GCP) and local legislation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and judged clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure greater than 140 mm Hg, diastolic&#xD;
             blood pressure greater than 90 mm Hg, or pulse rate outside the range of 50 to 90 mmHg&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Serum creatinine laboratory value out of the normal range&#xD;
&#xD;
          -  GFR (Glomerular Filtration Rate) &lt; 90 mL/ min at screening&#xD;
&#xD;
          -  Urinary toral protein/creatinine ratio &gt; 0,1 mg protein/ mg creatinine&#xD;
&#xD;
          -  Current or history of relevant kidney, urinary tract diseases or abnormalities (i.e.&#xD;
             nephrolithiasis, hydronephrosis, acute or chronic nephritis, renal injury, renal&#xD;
             failure, infections)&#xD;
&#xD;
          -  Further exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1333.43.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>July 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>December 23, 2014</last_update_submitted>
  <last_update_submitted_qc>December 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

